Skin Allergy to Azole Antifungal Agents for Systemic Use: A Review of the Literature

Author(s): Gianfranco Calogiuri, Lene H. Garvey, Eustachio Nettis, Paolo Romita, Elisabetta Di Leo, Riccardo Caruso, Lavjay Butani, Caterina Foti*

Journal Name: Recent Patents on Inflammation & Allergy Drug Discovery

Volume 13 , Issue 2 , 2019

Become EABM
Become Reviewer

Abstract:

Background: Antifungal azoles are the first-line agents used to treat topical and, above all, systemic mycosis. The latter could be life-threating infections in immunocompromised patients. Chemotherapeutic antibiotics, including antifungal azoles, may induce hypersensitivity reactions; however, such immunologic adverse reactions have not been defined and carefully investigated.

Objective: The study aims to provide an update on the evaluation and diagnosis of skin allergy to azole antifungal agents.

Methods: This is a systematic review performed on PubMed and Google Schoolbarusing using the key terms “allergy, hypersensitivity, anaphylaxis, immediate-type reaction, delayed-type reaction, ketoconazole, fluconazole, posaconazole, voriconazole, itraconazole, triazoles, imidazoles, antifungals, antimycotics”. The search strategy included meta-analyses, randomized controlled trials, clinical trials, observational studies, reviews and case reports.

Results: One hundred twenty-four articles matched our search terms. The most common adverse events reported were T-cell mediated delayed-type hypersensitivity reactions, fixed drug eruptions, exanthematous dermatitis, Steven-Johnson syndrome, toxic epidermal necrolysis and acute generalized exhanthematous pustulosis. Rarely a drug rash with eosinophilia systemic symptoms, has been described. Also, immediate-type reactions such as urticaria-angioedema or anaphylaxis have been reported following the administration of antifungal imidazoles, although not so frequently.

Conclusion: Despite their widespread use, triazoles seem to induce rare cutaneous hypersensitivity reactions, but the pathomechanisms, risk factors, diagnostic and management strategies, including skin tests and challenge tests, are little known and poorly investigated.

Keywords: Allergy, antifungals, dermatitis, hypersensitivity, imidazoles, rash, triazoles.

[1]
Verma AK, Arora SK, Arora JS, Rattan A. Azole compounds as therapeutic agents for fungal infections. US6670363 (2003).
[2]
Thompson GR III, Cadena J, Patterson TF. Overview of antifungal agents. Clin Chest Med 2009; 30(2): 203-15.
[http://dx.doi.org/10.1016/j.ccm.2009.02.001] [PMID: 19375628]
[3]
Sobel JD, Sobel R. Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species. Expert Opin Pharmacother 2018; 19(9): 971-7.
[http://dx.doi.org/10.1080/14656566.2018.1476490] [PMID: 29932786]
[4]
Arndt CA, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplack DG. Fluconazole penetration into cerebrospinal fluid: Implications for treating fungal infections of the central nervous system. J Infect Dis 1988; 157(1): 178-80.
[http://dx.doi.org/10.1093/infdis/157.1.178] [PMID: 2826606]
[5]
Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: Immunopharmacology of modern antifungals. Clin Infect Dis 2008; 47(2): 226-35.
[http://dx.doi.org/10.1086/589290] [PMID: 18540822]
[6]
Dodds Ashley ES, Russell L, Lewis JS, Craig M, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43: S28-39.
[http://dx.doi.org/10.1086/504492]
[7]
Raulin C, Frosch PJ. Contact allergy to imidazole antimycotics. Contact Dermat 1988; 18: 76-80.
[http://dx.doi.org/10.1111/cod.13146] [PMID: 30411354]
[8]
Dooms-Goossens A, Matura M, Drieghe J, Degreef H. Contact allergy to imidazoles used as antimycotic agents. Contact Dermat 1995; 33(2): 73-7.
[http://dx.doi.org/10.1111/j.1600-0536.1995.tb00504.x] [PMID: 8549147]
[9]
Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113(5): 832-6.
[http://dx.doi.org/10.1007/s40266-015-0249-x] [PMID: 25851216]
[10]
Posadas SJ, Pichler WJ. Delayed drug hypersensitivity reactions - new concepts. Clin Exp Allergy 2007; 37: 989-99.
[11]
González-Delgado P, Florido-Lopez F, Saenz de San Pedro B, Cuevas-Agusti M, Marin-Pozo JF. Hypersensitivity to ketoconazole. Ann Allergy 1994; 73(4): 326-8.
[PMID: 7524384]
[12]
Ensina LF, Tanno LK, Motta AA, Kalil J, Giavina-Bianchi P. Ketoconazole allergy. Clinics (São Paulo) 2009; 64(4): 373-4.
[http://dx.doi.org/10.1590/S1807-59322009000400018] [PMID: 19488598]
[13]
van Dijke CP, Veerman FR, Haverkamp HC. Anaphylactic reactions to ketoconazole. Br Med J (Clin Res Ed) 1983; 287(6406): 1673-9.
[http://dx.doi.org/10.1136/bmj.287.6406.1673] [PMID: 6315129]
[14]
Chen J, Song X, Yang P, Wang J. Appearance of anaphylactic shock after long-term intravenous itraconazole treatment. Ann Pharmacother 2009; 43(3): 537-41.
[http://dx.doi.org/10.1345/aph.1L343] [PMID: 19261964]
[15]
Martínez-Alonso JC, Domínguez-Ortega FJ, Fuentes-Gonzalo MJ. Urticaria and angioedema due to itraconazole. Allergy 2003; 58(12): 1317-8.
[http://dx.doi.org/10.1046/j.0105-4538.2003.00316.x] [PMID: 14616112]
[16]
Schmutz JL, Barbaud A, Trechot P. Urticaria and angioedema due to itraconazole. Ann Dermatol Venereol 2005; 132: 403-10.
[http://dx.doi.org/10.1016/S0151-9638(05)79298-X]
[17]
Neuhaus G, Pavic N, Pletscher M. Anaphylactic reaction after oral fluconazole. BMJ 1991; 302(6788): 1341-7.
[http://dx.doi.org/10.1136/bmj.302.6788.1341-b] [PMID: 2059703]
[18]
Koklu E, Kalay S, Koklu S, Ariguloglu EA. Fluconazole administration leading to anaphylactic shock in a preterm newborn. Neonatal Netw 2014; 33(2): 83-5.
[http://dx.doi.org/10.1891/0730-0832.33.2.83] [PMID: 24589899]
[19]
Randolph C, Kaplan C, Fraser B. Rapid desensitization to fluconazole (Diflucan). Ann Allergy Asthma Immunol 2008; 100(6): 616-7.
[http://dx.doi.org/10.1016/S1081-1206(10)60063-4] [PMID: 18592829]
[20]
Abbott M, Hughes DL, Patel R, Kinghorn GR. Angio-oedema after fluconazole. Lancet 1991; 338(8767): 633.
[http://dx.doi.org/10.1016/0140-6736(91)90643-4] [PMID: 1679171]
[21]
Singh Mahal H. Fluconazole-induced type-1 Kounis syndrome. Am J Ther 2016; 23(3): e961-2.
[http://dx.doi.org/10.1097/MJT.0000000000000113] [PMID: 26938747]
[22]
Gençer S, Ozer S, Demirhan G, Ak O, Batirel A. Angio-oedema as an unusual tolerable side effect of voriconazole therapy. J Med Microbiol 2008; 57(Pt 8): 1028-31.
[http://dx.doi.org/10.1099/jmm.0.47299-0] [PMID: 18628507]
[23]
Morales MK, Harris C, Shoham S. Graded isavuconazole introduction in a patient with voriconazole allergy. Transpl Infect Dis 2017; 19(6)
[http://dx.doi.org/10.1111/tid.12772] [PMID: 28851131]
[24]
Jean T, Kwong K. Successful desensitization of voriconazole in an immunosuppressed pediatric patient. J Allergy Clin Immunol Pract 2015; 3(4): 637-8.
[http://dx.doi.org/10.1016/j.jaip.2015.02.008] [PMID: 25800818]
[25]
Eiden C, Peyrière H, Cociglio M, Djezzar S, Hansel S, Blayac JP, et al. Adverse effects of voriconazole: Analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007; 41(5): 755-63.
[http://dx.doi.org/10.1345/aph.1H671] [PMID: 17456542]
[26]
Ozkaya-Bayazit E, Bayazit H, Ozarmagan G. Drug related clinical pattern in fixed drug eruption. Eur J Dermatol 2000; 10(4): 288-91.
[PMID: 10846256]
[27]
Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Allergol Select 2017; 1(1): 96-108.
[http://dx.doi.org/10.5414/ALX01508E] [PMID: 30402608]
[28]
Bharija SC, Belhaj MS. Ketoconazole-induced fixed drug eruption. Int J Dermatol 1988; 27(4): 278-9.
[http://dx.doi.org/10.1111/j.1365-4362.1988.tb03236.x] [PMID: 2968961]
[29]
Kastalli S, El Aïdli S, Lakhoua G, Daghfous R. Genital fixed drug eruption induced by miconazole with positive provocation test. Tunis Med 2014; 92(11): 703.
[PMID: 25867162]
[30]
Guliani A, Chauhan A. Fixed drug eruption due to itraconazole: A rare occurence. Postgrad Med J 2019; 95(1124): 340-1.
[http://dx.doi.org/10.1136/postgradmedj-2019-136680] [PMID: 31085618]
[31]
Morgan JM, Carmichael AJ. Fixed drug eruption with fluconazole. BMJ 1994; 308(6926): 454.
[http://dx.doi.org/10.1136/bmj.308.6926.454a] [PMID: 8124179]
[32]
Heikkilä H, Timonen K, Stubb S. Fixed drug eruption due to fluconazole. J Am Acad Dermatol 2000; 42(5 Pt 2): 883-4.
[http://dx.doi.org/10.1016/S0190-9622(00)90262-7] [PMID: 10767695]
[33]
Ghislain PD, Ghislain E. Fixed drug eruption due to fluconazole: A third case. J Am Acad Dermatol 2002; 46(3): 467.
[http://dx.doi.org/10.1067/mjd.2002.118356] [PMID: 11862192]
[34]
Coondoo ABR. Fluconazole induced fixed drug eruption. Int J Dermatol 2003; 48: 61.
[35]
Lane JE, Buckthal J, Davis LS. Fixed drug eruption due to fluconazole. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95(2): 129-30.
[http://dx.doi.org/10.1067/moe.2003.14] [PMID: 12599328]
[36]
Goel A, Jain C. Fluconazole induced fixed drug eruption: A rare offender. J Dermatol 2004; 31(4): 345-6.
[http://dx.doi.org/10.1111/j.1346-8138.2004.tb00683.x] [PMID: 15187332]
[37]
Gupta R, Thami GP. Fixed drug eruption caused by itraconazole: Reactivity and cross reactivity. J Am Acad Dermatol 2008; 58(3): 521-2.
[http://dx.doi.org/10.1016/j.jaad.2006.06.014] [PMID: 18280361]
[38]
Tavallaee M, Rad MM. Fixed drug eruption resulting from fluconazole use: A case report. J Med Case Reports 2009; 3: 7368-77.
[http://dx.doi.org/10.4076/1752-1947-3-7368] [PMID: 19830193]
[39]
Walling HW, Swick BL. Cutaneous fixed drug eruption to fluconazole. J Drugs Dermatol 2010; 9(8): 1025-8.
[PMID: 20684158]
[40]
Kim CY, Kim JG, Oh CW. Fluconazole induced fixed drug eruption. Ann Dermatol 2011; 23(Suppl. 1): S1-3.
[http://dx.doi.org/10.5021/ad.2011.23.S1.S1] [PMID: 22028550]
[41]
Beecker J, Colantonio S. Fixed drug eruption due to fluconazole. CMAJ 2012; 184(6): 675-83.
[http://dx.doi.org/10.1503/cmaj.111530] [PMID: 22231677]
[42]
Nakai N, Katoh N. Fixed drug eruption caused by fluconazole: A case report and mini-review of the literature. Allergol Int 2013; 62: 139-41.
[http://dx.doi.org/10.2332/allergolint.12-LE-0464]
[43]
Gaiser CA, Sabatino D. Fluconazole-induced fixed drug eruption. J Clin Aesthet Dermatol 2013; 6(3): 44-5.
[PMID: 23556037]
[44]
Vora RV, Mehta MJ, Diwan NG, Gor AP, Gajjar B. Fixed drug eruption due to fluconazole: A case report. Natl J Physiol Pharm Pharmacol 2014; 4: 255-7.
[http://dx.doi.org/10.5455/njppp.2014.4.040620142]
[45]
Santra R, Pramanik S, Raychaudhuri P. Fixed drug eruption due to fluconazole: Not so uncommon now-a-days. J Clin Diagn Res 2014; 8(11): HL01.
[http://dx.doi.org/10.7860/JCDR/2014/7644.5159] [PMID: 25584246]
[46]
Waldman L, Reddy SB, Kassim A, Dettloff J, Reddy VB. Neutrophilic fixed drug eruption to fluconazole. Am J Dermatopathol 2015; 37(7): 574-6.
[http://dx.doi.org/10.1097/DAD.0000000000000157] [PMID: 25072682]
[47]
Lai O, Hsu S. Fixed drug eruption related to fluconazole. Dermatol Online J 2016; 22 pii.
[48]
Demir S, Cetin EA, Unal D, Coskun R, Olgac M, Gelincik A, et al. Generalized fixed drug eruption induced by fluconazole without cross-reactivity to itraconazole: Lymphocyte transformation test confirms the diagnosis. Drug Saf Case Rep 2018; 5(1): 2-15.
[http://dx.doi.org/10.1007/s40800-017-0067-7] [PMID: 29294202]
[49]
Quint T, Wöhrl S, Kinaciyan T. Fixed drug eruption caused by fluconazole-An underdiagnosed but recurrent problem. Contact Dermat 2019; 80(3): 172-3.
[http://dx.doi.org/10.1111/cod.13149] [PMID: 30417394]
[50]
Benedix F, Schilling M, Schaller M, Röcken M, Biedermann T. A young woman with recurrent vesicles on the lower lip: Fixed drug eruption mimicking herpes simplex. Acta Derm Venereol 2008; 88(5): 491-4.
[http://dx.doi.org/10.2340/00015555-0519] [PMID: 18779889]
[51]
Alfonso N, Rane P, Dang A, Rataboli P, Goel H. Fluconazole induced herpes labialis like lesions in an adult male. Austr Med J 2009; 14: 246-7.
[52]
González-Fernández T, López-Freire S, Juangorena M, Méndez-Brea P, Vázquez-Veiga H. Herpes-like eruption due to fluconazole. J Investig Allergol Clin Immunol 2015; 25(2): 135-6.
[PMID: 25997308]
[53]
Jensen ZN, Bygum A, Damkier P. Fluconazole-induced fixed drug eruption imitating herpes labialis with erythema multiforme. Eur J Dermatol 2012; 22(5): 693-4.
[http://dx.doi.org/10.1684/ejd.2012.1806] [PMID: 22858871]
[54]
Schneller-Pavelescu L, Ochando-Ibernón G, Vergara-de Caso E, Silvestre-Salvador JF. Herpes simplex-like fixed drug eruption induced by fluconazole without cross-reactivity to itraconazole. Dermatitis 2019; 30(2): 174-5.
[http://dx.doi.org/10.1097/DER.0000000000000451] [PMID: 30829805]
[55]
Sławińska M, Barańska-Rybak W, Wilkowska A, Nowicki R. Bullous fixed drug eruption due to fluconazole, imitating herpes simplex. Clin Exp Dermatol 2017; 42(5): 544-5.
[http://dx.doi.org/10.1111/ced.13098] [PMID: 28512848]
[56]
Nath AK, Adityan B, Thappa DM. Multifocal bullous fixed drug eruption due to fluconazole. Indian J Dermatol 2008; 53(3): 156-7.
[http://dx.doi.org/10.4103/0019-5154.43212] [PMID: 19882020]
[57]
Choudhury S, Loc BP, Debbarma RR, Das A. Fluconazole induced multifocal bullous eruptions: A case report. Int J Basic Clin Pharmacol 2016; 5: 1681-3.
[http://dx.doi.org/10.18203/2319-2003.ijbcp20162492]
[58]
Bittleman DB, Stapleton J, Casale TB. Report of successful desensitization to itraconazole. J Allergy Clin Immunol 1994; 94(2 Pt 1): 270-1.
[http://dx.doi.org/10.1053/ai.1994.v94.a55252] [PMID: 8064084]
[59]
Batinac T, Zamolo G, Troselj-Vukić B, Biljan D, Petranović D, Kujundzić M. Maculopapular eruption secondary to itraconazole. Coll Antropol 2008; 32(2): 649-51.
[PMID: 18756926]
[60]
Goto Y, Kono T, Teramae K, Ishii M. Itraconazole-induced drug eruption confirmed by challenge test. Acta Derm Venereol 2000; 80(1): 72-9.
[http://dx.doi.org/10.1080/000155500750012694] [PMID: 10721851]
[61]
Di Leo E, Nettis E, Priore MG, Ferrannini A, Vacca A. Maculopapular rash due to fluconazole. Clin Exp Dermatol 2009; 34(3): 404-12.
[http://dx.doi.org/10.1111/j.1365-2230.2008.02895.x] [PMID: 18627382]
[62]
Kahana M, Levy A, Yaron-Shiffer O, Schewach-Millet M. Drug eruption following ketoconazole therapy. Arch Dermatol 1984; 120(7): 837-42.
[http://dx.doi.org/10.1001/archderm.1984.01650430023003] [PMID: 6329105]
[63]
van Ketel WG. An allergic eruption probably caused by ketoconazole. Contact Dermat 1983; 9(4): 313-3.
[http://dx.doi.org/10.1111/j.1600-0536.1983.tb04398.x] [PMID: 6311485]
[64]
Kramer KE, Yaar M, Andersen W. Purpuric drug eruption secondary to itraconazole. J Am Acad Dermatol 1997; 37(6): 994-5.
[http://dx.doi.org/10.1016/S0190-9622(97)70080-X] [PMID: 9418771]
[65]
Su FW, Perumalswami P, Grammer LC. Acute hepatitis and rash to fluconazole. Allergy 2003; 58(11): 1215-6.
[http://dx.doi.org/10.1046/j.0105-4538.2003.00318.x] [PMID: 14616149]
[66]
Pinto A, Chan RC. Lack of allergic cross-reactivity between fluconazole and voriconazole. Antimicrob Agents Chemother 2009; 53(4): 1715-6.
[http://dx.doi.org/10.1128/AAC.01500-08] [PMID: 19164151]
[67]
Alffenaar JWC, van Assen S, de Monchy JGR, Uges DRA, Kosterink JGW, van der Werf TS. Intravenous voriconazole after toxic oral administration. Antimicrob Agents Chemother 2010; 54(6): 2741-2.
[http://dx.doi.org/10.1128/AAC.01193-09] [PMID: 20385853]
[68]
Takahashi T, Hitani A, Yamada H, Nakamura T, Iwamoto A. Desenitization to fluconazole in an AIDS patient. Ann Pharmacother 2001; 35(5): 642-3.
[http://dx.doi.org/10.1345/aph.10285] [PMID: 11346073]
[69]
Jariwala S, Vernon N, de Vos G. A novel method of desensitization for fluconazole hypersensitivity in a patient with AIDS. Ann Allergy Asthma Immunol 2011; 106(6): 542-3.
[http://dx.doi.org/10.1016/j.anai.2011.02.020] [PMID: 21624759]
[70]
Fernandez L, Maquiera E, Rodriguez F, Picans I, Duque S. Systemic contact dermatitis from miconazole. Contact Dermat 1996; 34(3): 217.
[http://dx.doi.org/10.1111/j.1600-0536.1996.tb02178.x] [PMID: 8833469]
[71]
Rademaker M, Barker S. Contact dermatitis to a canine anti-dandruff shampoo. Australas J Dermatol 2007; 48(1): 62-3.
[http://dx.doi.org/10.1111/j.1440-0960.2007.00329.x] [PMID: 17222309]
[72]
Imafuku S, Nakayama J. Contact allergy to ketoconazole cross-sensitive to miconazole. Clin Exp Dermatol 2009; 34(3): 411-2.
[http://dx.doi.org/10.1111/j.1365-2230.2008.02942.x] [PMID: 19120394]
[73]
Erdmann S, Hertl M, Merk HF. Contact dermatitis from clotrimazole with positive patch-test reactions also to croconazole and itraconazole. Contact Dermat 1999; 40(1): 47-8.
[http://dx.doi.org/10.1111/j.1600-0536.1999.tb05977.x] [PMID: 9928806]
[74]
Nasir S, Goldsmith P. Anogenital allergic contact dermatitis caused by methylchloroisothiazolinone, methylisothiazolinone and topical clotrimazole with subsequent generalized exanthem triggered by oral fluconazole. Contact Dermat 2016; 74(5): 296-7.
[http://dx.doi.org/10.1111/cod.12513] [PMID: 27040872]
[75]
Stingeni L, Rigano L, Lionetti N, Bianchi L, Tramontana M, Foti C, et al. Sensitivity to imidazoles/nitroimidazoles in subjects sensitized to methylchloroisothiazolinone/methylisothiazolinone: A simple coincidence? Contact Dermat 2019; 80(3): 181-3.
[http://dx.doi.org/10.1111/cod.13158] [PMID: 30468019]
[76]
Tan SC, Tan JW. Symmetrical drug-related intertriginous and flexural exanthema. Curr Opin Allergy Clin Immunol 2011; 11(4): 313-8.
[http://dx.doi.org/10.1097/ACI.0b013e3283489d5f] [PMID: 21659857]
[77]
Gulec AI, Uslu E, Başkan E, Yavuzcan G, Aliagaoglu C. Baboon syndrome induced by ketoconazole. Cutan Ocul Toxicol 2014; 33(4): 339-41.
[http://dx.doi.org/10.3109/15569527.2013.870187] [PMID: 24641119]
[78]
Mohapatra M, Panda M, Kar BR, Raj C. Symmetric drug-related intertriginous and flexural exanthema due to itraconazole: An uncommon side effect of a commonly used drug. Indian Dermatol Online J 2017; 8(6): 501-3.
[http://dx.doi.org/10.4103/idoj.IDOJ_179_17] [PMID: 29204404]
[79]
Nanda S. A case of SDIFE induced by fluconazole. J Am Acad Dermatol 2016; 74(1): 89-95.
[80]
Bianchi L, Hansel K, Antonelli E, Bellini V, Stingeni L. Contact allergy to isoconazole nitrate with unusual spreading over extensive regions. Contact Dermat 2017; 76(4): 243-5.
[http://dx.doi.org/10.1111/cod.12688] [PMID: 28317189]
[81]
Patruno C, Megna M, Bianca D, Patri A, Balato N. Erythema multiforme-like allergic contact dermatitis due to tioconazole. Clin Dermatol 2014; 2: 48-50.
[82]
Park H, Knowles S, Shear NH. Serum sickness-like reaction to itraconazole. Ann Pharmacother 1998; 32(11): 1249-55.
[http://dx.doi.org/10.1345/aph.17432] [PMID: 9825096]
[83]
Tang MM, Corti MAM, Stirnimann R, et al. Severe cutaneous allergic reactions following topical antifungal therapy. Contact Dermat 2013; 68(1): 56-7.
[http://dx.doi.org/10.1111/j.1600-0536.2012.02151.x] [PMID: 23227869]
[84]
Gravante G, Delogu D, Marianetti M, Esposito G, Montone A. Toxic epidermal necrolysis and Steven-Johnson syndrome in oncologic patients. Eur Rev Med Pharmacol Sci 2007; 11(4): 269-74.
[PMID: 17876963]
[85]
Gussenhoven MJ, Haak A, Peereboom-Wynia JD, van’t Wout JW. Stevens-Johnson syndrome after fluconazole. Lancet 1991; 338(8759): 120-6.
[http://dx.doi.org/10.1016/0140-6736(91)90112-3] [PMID: 1676446]
[86]
Azón-Masoliver A, Vilaplana J. Fluconazole-induced toxic epidermal necrolysis in a patient with human immunodeficiency virus infection. Dermatology (Basel) 1993; 187(4): 268-9.
[http://dx.doi.org/10.1159/000247261] [PMID: 8274783]
[87]
Monastirli A, Pasmatzi E, Vryzaki E, Georgiou S, Tsambaos D. Fluconazole-induced Stevens-Johnson syndrome in a HIV-negative patient. Acta Derm Venereol 2008; 88(5): 521-2.
[http://dx.doi.org/10.2340/00015555-0489] [PMID: 18779900]
[88]
Craythorne E, Creamer D. Stevens-Johnson syndrome due to prophylactic fluconazole in two patients with liver failure. Clin Exp Dermatol 2009; 34(7): e389-90.
[http://dx.doi.org/10.1111/j.1365-2230.2009.03365.x] [PMID: 19548943]
[89]
Ofoma UR, Chapnick EK. Fluconazole induced toxic epidermal necrolysis: A case report. Cases J 2009; 2: 9071.
[http://dx.doi.org/10.1186/1757-1626-2-9071] [PMID: 20062708]
[90]
Thiyanaratnam J, Cohen PR, Powell S. Fluconazole-associated Stevens-Johnson syndrome. J Drugs Dermatol 2010; 9(10): 1272-5.
[PMID: 20941954]
[91]
Pasmatzi E, Monastirli A, Georgiou S, Sgouros G, Tsambaos D. Short-term and low-dose oral fluconazole treatment can cause Stevens-Johnson syndrome in HIV-negative patients. J Drugs Dermatol 2011; 10(12): 1360-7.
[PMID: 22134558]
[92]
George J, Sharma A, Dixit R, Chhabra N, Sharma S. Toxic epidermal necrolysis caused by fluconazole in a patient with human immunodeficiency virus infection. J Pharmacol Pharmacother 2012; 3(3): 276-8.
[http://dx.doi.org/10.4103/0976-500X.99445] [PMID: 23129968]
[93]
Islam S, Singer M, Kulhanjian JA. Toxic epidermal necrolysis in a neonate receiving fluconazole. J Perinatol 2014; 34(10): 792-4.
[http://dx.doi.org/10.1038/jp.2014.92] [PMID: 25263725]
[94]
Huang DB, Wu JJ, Lahart CJ. Toxic epidermal necrolysis as a complication of treatment with voriconazole. South Med J 2004; 97(11): 1116-7.
[http://dx.doi.org/10.1097/01.SMJ.0000144618.80128.F9] [PMID: 15586606]
[95]
Curigliano G, Formica V, De Pas T, Spitaleri G, Pietri E, Fazio N, et al. Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. Ann Oncol 2006; 17(7): 1174-5.
[http://dx.doi.org/10.1093/annonc/mdj126] [PMID: 16410362]
[96]
Gomulka J, Wilson BD, Joyce JC. Toxic epidermal necrolysis due to voriconazole: Case report and review. Dermatol Online J 2014; 20(9): 20.
[PMID: 25244163]
[97]
Lester LJ, Brantley JS, Kelso RL, Kelly BC, Petitt MS, Wilkerson MG. Severe cutaneous adverse drug reaction due to fluconazole. J Drugs Dermatol 2008; 7(11): 1084-7.
[PMID: 19110744]
[98]
Eloranta K, Karakorpi H, Jeskanen L, Kluger N. Photo-distributed Stevens-Johnson syndrome associated with oral itraconazole. Int J Dermatol 2016; 55(9): e508-10.
[http://dx.doi.org/10.1111/ijd.13278] [PMID: 27028785]
[99]
Alvarez-Fernández JG, Castaño-Suárez E, Cornejo-Navarro P, de la Fuente EG, Ortiz de Frutos FJ, Iglesias-Diez L. Photosensitivity induced by oral itraconazole. J Eur Acad Dermatol Venereol 2000; 14(6): 501-3.
[http://dx.doi.org/10.1046/j.1468-3083.2000.00164.x] [PMID: 11444275]
[100]
Willis ZI, Boyd AS, Di Pentima MC. Phototoxicity, pseudoporphyria, and photo-onycholysis due to voriconazole in a pediatric patient with leukemia and invasive aspergillosis. J Pediatric Infect Dis Soc 2015; 4(2): e22-4.
[http://dx.doi.org/10.1093/jpids/piu065] [PMID: 26407422]
[101]
Haylett AK, Felton S, Denning DW, Rhodes LE. Voriconazole-induced photosensitivity: Photobiological assessment of a case series of 12 patients. Br J Dermatol 2013; 168(1): 179-85.
[http://dx.doi.org/10.1111/j.1365-2133.2012.11196.x] [PMID: 22860570]
[102]
Sheu J, Hawryluk EB, Guo D, London WB, Huang JT. Voriconazole phototoxicity in children: A retrospective review. J Am Acad Dermatol 2015; 72(2): 314-20.
[http://dx.doi.org/10.1016/j.jaad.2014.10.023] [PMID: 25481710]
[103]
Miteva L, Kadurina M, Schwartz RA. Childhood acute generalized exanthematous pustulosis induced by oral ketoconazole. Acta Dermatovenerol Croat 2010; 18(4): 267-70.
[PMID: 21251445]
[104]
Heymann WR, Manders SM. Itraconazole-induced acute generalized exanthemic pustulosis. J Am Acad Dermatol 1995; 33(1): 130-1.
[http://dx.doi.org/10.1016/0190-9622(95)90038-1] [PMID: 7601931]
[105]
Park YM, Kim JW, Kim CW. Acute generalized exanthematous pustulosis induced by itraconazole. J Am Acad Dermatol 1997; 36(5 Pt 1): 794-6.
[http://dx.doi.org/10.1016/S0190-9622(97)80353-2] [PMID: 9146550]
[106]
Cançado GGL, Fujiwara RT, Freitas PA, Correa-Oliveira R, Bethony JM. Acute generalized exanthematous pustulosis induced by itraconazole: An immunological approach. Clin Exp Dermatol 2009; 34(8): e709-11.
[http://dx.doi.org/10.1111/j.1365-2230.2009.03440.x] [PMID: 20055840]
[107]
Alsadhan A, Taher M, Krol A. Acute generalized exanthematous pustulosis induced by oral fluconazole. J Cutan Med Surg 2002; 6(2): 122-4.
[http://dx.doi.org/10.1177/120347540200600205] [PMID: 11992184]
[108]
Di Lernia V, Ricci C. Fluconazole-induced acute generalized exanthematous pustulosis. Indian J Dermatol 2015; 60(2): 212-9.
[PMID: 25814733]
[109]
Fabre B, Albès B, Belhadjali H, Bazex J. Acute generalized exanthematous pustulosis due to fluconazole. Ann Dermatol Venereol 2002; 129(3): 294-7.
[PMID: 11988684]
[110]
Kaneko Y, Kageyama R, Hashizume H. Agranulocytosis associated with voriconazole-induced hypersensitivity syndrome. J Dermatol 2018; 45(5): e118-9.
[http://dx.doi.org/10.1111/1346-8138.14142] [PMID: 29168223]
[111]
Sánchez-Borges M, González-Aveledo LA. Fixed drug eruptions induced by cross-reactive imidazoles. Allergol Immunopathol (Madr) 2011; 39(4): 246-7.
[http://dx.doi.org/10.1016/j.aller.2010.07.003] [PMID: 21146916]
[112]
Stingeni L, Bianchi L, Hansel K, Corazza M, Gallo R, Guarneri F, et al. Italian guidelines in patch testing adapted from the European Society of Contact Dermatitis (ESCD). G Ital Dermatol Venereol 2019; 154(3): 227-53.
[http://dx.doi.org/10.23736/S0392-0488.19.06301-6] [PMID: 30717577]
[113]
González P, Soriano V, López P, Niveiro E. Anaphylaxis to proton pump inhibitors. Allergol Immunopathol (Madr) 2002; 30(6): 342-3.
[http://dx.doi.org/10.1016/S0301-0546(02)79150-7] [PMID: 12464168]
[114]
Motley RJ, Reynolds AJ. Contact allergy to 2,4-dichlorophenylethyl imidazole derivatives. Contact Dermat 1988; 19(5): 381-2.
[http://dx.doi.org/10.1111/j.1600-0536.1988.tb02959.x] [PMID: 2976655]
[115]
Baes H. Contact sensitivity to miconazole with ortho-chloro cross-sensitivity to other imidazoles. Contact Dermat 1991; 24(2): 89-93.
[http://dx.doi.org/10.1111/j.1600-0536.1991.tb01658.x] [PMID: 1828223]
[116]
Abhinav C, Mahajan VK, Mehta KS, Chauhan PS. Allergic contact dermatitis due to clotrimazole with cross-reaction to miconazole. Indian J Dermatol Venereol Leprol 2015; 81(1): 80-2.
[http://dx.doi.org/10.4103/0378-6323.148592] [PMID: 25566914]
[117]
Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004; 32(10): 1121-31.
[http://dx.doi.org/10.1124/dmd.104.000315] [PMID: 15242978]
[118]
Tanaka T, Sato T, Yokozeki H. Allergic contact dermatitis from luliconazole: Implication of the dithioacetal structure. Acta Dermato- Venereol 2006; 270-1.
[119]
Umebayashi Y, Ito S. Allergic contact dermatitis due to both lanoconazole and neticonazole ointments. Contact Dermat 2001; 44(1): 48-9.
[http://dx.doi.org/10.1034/j.1600-0536.2001.440107-15.x] [PMID: 11156023]
[120]
Bavbek S, Yilmaz İ, Sözener ZÇ. Fixed drug eruption caused by ornidazole and fluconazole but not isoconazole, itraconazole, ketoconazole and metronidazole. J Dermatol 2013; 40(2): 134-5.
[http://dx.doi.org/10.1111/1346-8138.12023] [PMID: 23110686]
[121]
Sanmukhani J, Shah V, Baxi S, Tripathi C. Fixed drug eruption with ornidazole having cross-sensitivity to secnidazole but not to other nitro-imidazole compounds: A case report. Br J Clin Pharmacol 2010; 69(6): 703-4.
[http://dx.doi.org/10.1111/j.1365-2125.2010.03651.x] [PMID: 20565463]
[122]
Aerts O, Goossens A, Lambert J, Lepoittevin JP. Contact allergy caused by isothiazolinone derivatives: An overview of non-cosmetic and unusual cosmetic sources. Eur J Dermatol 2017; 27(2): 115-22.
[http://dx.doi.org/10.1684/ejd.2016.2951] [PMID: 28174143]
[123]
Wolf R, Orion E, Matz H. Co-existing sensitivity to metronidazole and isothiazolinone. Clin Exp Dermatol 2003; 28(5): 506-7.
[http://dx.doi.org/10.1046/j.1365-2230.2003.01364.x] [PMID: 12950340]
[124]
Craig TJ, Peralta F, Boggavarapu J. Desensitization for fluconazole hypersensitivity. J Allergy Clin Immunol 1996; 98(4): 845-6.
[http://dx.doi.org/10.1016/S0091-6749(96)70136-7] [PMID: 8876563]
[125]
Lepoittevin JP, Drieghe J, Dooms-Goossens A. Studies in patients with corticosteroid contact allergy. Understanding cross-reactivity among different steroids. Arch Dermatol 1995; 131(1): 31-7.
[http://dx.doi.org/10.1001/archderm.1995.01690130033006] [PMID: 7826093]
[126]
Benjamin Lash D, Jolliff J, Munoz A, Heidari A. Cross-reactivity between voriconazole, fluconazole and itraconazole. J Clin Pharm Ther 2016; 41(5): 566-7.
[http://dx.doi.org/10.1111/jcpt.12417] [PMID: 27430151]
[127]
Rankin BT, Jariwala S. Graded challenge protocol for fluconazole hypersensitivity in a patient with cryptococcal pneumonitis. Ann Allergy Asthma Immunol 2012; 108(6): 466-72.
[http://dx.doi.org/10.1016/j.anai.2012.04.005] [PMID: 22626606]
[128]
Anonimous. Antifungal drugs. Medical Letter 2009; 88: 95-102.
[129]
Douglas R, Spelman D, Czarny D, O’Hehir R. Desensitization to itraconazole. J Allergy Clin Immunol 1997; 99(2): 269-78.
[http://dx.doi.org/10.1016/S0091-6749(97)70111-8] [PMID: 9042060]
[130]
Oriel R, Kaplan B. Effective oral induction of drug tolerance to voriconazole in a pediatric patient with delayed hypersensitivity. Ann Allergy Asthma Immunol 2016; 22: 47-52.
[http://dx.doi.org/10.1016/j.anai.2016.09.055]
[131]
Greenberger P. Desensitization and test-dosing for the drug-allergic patient. Ann Allergy Asthma Immunol 2000; 85(4): 250-1.
[http://dx.doi.org/10.1016/S1081-1206(10)62526-4] [PMID: 11061466]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 2
Year: 2019
Page: [144 - 157]
Pages: 14
DOI: 10.2174/1872213X13666190919162414

Article Metrics

PDF: 34
HTML: 18